Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Consensus Elusive On Design Of Breast Cancer Ablation Registry

This article was originally published in The Gray Sheet

Executive Summary

Cost and patient participation will probably be major impediments in developing a registry of breast cancer ablation clinical trials, according to stakeholder comments to FDA

You may also be interested in...

Frontiers in Breast Cancer Research, Part II: Developments in Partial Breast Irradiation and Tumor Ablation

As the use of breast conserving lumpectomy expands as a treatment for early-stage breast cancer, interest has surged in alternatives to whole breast irradiation. Follow-on radiation treatment is crucial to the success of this therapy, but a significant number of women are either unable or unwilling to undergo the typical treatment course involving five to seven weeks of daily radiation therapy. The device industry is responding with technologies aimed at delivering post-lumpectomy radiation therapy in a more convenient, potentially safer way.

FDA Workshop Weighs Breast Cancer Ablation Benefits, Trial Protocol Issues

Stakeholders debating appropriate feasibility study protocol for image-guided thermal ablation of early-stage breast cancer are cautioning that increased use of advanced imaging for the procedures may counter some of the anticipated cost benefits

FDA Proposes Registry On Thermal Ablation For Breast Cancer

FDA says the development of a patient registry might help industry design better early-stage clinical trials for evaluating ablation as an alternative breast tumor treatment to more invasive surgery

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts